Fig. 3From: Implementing the EffTox dose-finding design in the Matchpoint trialPosterior utility after 15 patients. Posterior densities of the utility of doses 3 and 4. In contrast to Fig. 2, after 15 patients with outcomes 2NNN 3ENN 4EBE 3TEE 4NEE, the posterior utilities are quite distinct and dose ambivalence is much less likelyBack to article page